ERErle Refsum

Erle Refsum

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Erle Refsum has a total of 73 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Topical retinoid use in women of reproductive age and risk of major congenital malformations in exposed pregnancies: a Nordic cohort study

    by Erle Refsum, Kari Furu, Carolyn E Cesta, Mette Nørgaard, Felix Wittström, Helga Zoega, Sinna P Ulrichsen, Jacqueline M Cohen

    Background: Topical retinoids are used to treat mild to moderate acne and should be avoided during pregnancy as a precaution given the teratogenic effect of systemic isotretinoin, despite limited safety data. Objectives: To describe recent trends in the prevalence of topical retinoid use in women of reproductive age and to estimate risk of major congenital malformations (MCMs) associated with exposure of topical retinoids in early pregnancy. Methods: Using publicly available nationwide data we estimated the annual prevalence of topical retinoid use in women of reproductive age (15–44 years) 2006–2024 in Denmark, Iceland, Norway and Sweden. We subsequently used linked individual-level data to perform a population-based cohort study using nationwide registers to estimate prevalence of use during pregnancy and risk of MCM. We included all infants with a gestational age of at least 22 weeks in Denmark, Iceland, Norway and Sweden from 1996 to 2020. We compared risks of nongenetic MCM among infants with first-trimester exposure to topical retinoids with: (i) unexposed infants and (ii) infants with first-trimester exposure to topical azelaic acid or topical clindamycin. We estimated adjusted risk ratios (aRRs) with log-binomial regression, adjusting for country of birth, maternal age, and birth year. Results: The prevalence of topical retinoid use among women of reproductive age in Denmark, Iceland, Norway and Sweden increased from 8.7 per 1000 in 2006 to 28.5 per 1000 in 2024. Of 3 869 586 infants included in the cohort, 0.86 per 1000 were exposed to topical retinoids in the first trimester. Among infants exposed to topical retinoids, 3.3% had any MCM (71 of 2172), compared with 3.0% among unexposed (111 404 of 3 671 023) [aRR 1.1, 95% confidence interval (CI) 0.87–1.38] and 2.6% among infants exposed to azelaic acid or clindamycin (295 of 11 139) (aRR 1.1, 95% CI 0.87–1.47). Conclusions: We observed a 3.3-fold increase in topical retinoid use over the past 18 years among women of reproductive age in the Nordic countries. We did not observe an increased risk of MCM associated with use of topical retinoids. Limiting to pregnancies resulting in a birth could underestimate both the prevalence of topical retinoid exposure and MCM risk.


  • Open Access

    Temporal trends in surgical treatment of inflammatory bowel disease following introduction of biological drugs in Norway and Sweden

    by Amanda Högdén, Vera Perrin, Hans-Olov Adami, Mette Kalager, Tine Jess, Weimin Ye, Jessica Young, Lise Mørkved Helsingen, Erle Refsum, Johannes Blom

    Objective The advent of biological drugs has revolutionised management of inflammatory bowel disease (IBD). However, the extent to which these novel pharmacological drugs have reduced the need for surgical treatment remains incompletely quantified. We aimed to investigate the risk of first, major surgery in IBD in a population-based, large epidemiological study. Methods We empanelled a cohort comprising all 85 974 patients diagnosed with ulcerative colitis (UC) and 42 760 with Crohn’s disease (CD) in Norway and Sweden in 1987 through 2017. We used log-rank tests to compare the cumulative probability of surgical treatment for UC and CD. Using multivariable Cox proportional hazards models, we estimated hazard ratios (HR) with 95% CIs by year of diagnosis, age, sex and extent of disease. Results During a mean follow-up of 9.9 years, surgery was undertaken in 11 187 (13.0%) patients with UC (12.3 per 1000 person-years) and in 11 307 (26.4%) patients with CD (30.0 per 1000 person-years). In UC, the cumulative 5-year probability of surgery decreased from 16.2% in patients diagnosed in 1987–1994 to 5.8% in those diagnosed in 2011–2017 (pConclusions Following the introduction of biologic drugs, the need for surgical treatments has been dramatically reduced in patients with UC and moderately reduced in patients with CD.


  • Open Access

    Risk of malignant lymphomas in patients with inflammatory bowel disease: a population-based cohort study

    by Jingru Yu, Erle Refsum, Paulina Wieszczy, Lise M Helsingen, Vera Perrin, Amanda Högdén, Magnus Løberg, Johannes Blom, Michael Bretthauer, Hans-Olov Adami, et al.

    Objective To estimate the risk of non-Hodgkin’s lymphoma (NHL) and Hodgkin’s lymphoma (HL) in patients with inflammatory bowel disease (IBD). Design We undertook a two-country population cohort study with all patients diagnosed with IBD in Norway and Sweden from 1987 and 1993 through 2015 and 2016, respectively, and analysed the risk of NHL and HL. In Sweden, we also analysed prescriptions of thiopurines and anti-tumour necrosis factor (TNF)-α therapy from 2005. We calculated standardised incidence ratios (SIRs) with 95% CIs using the general populations as reference. Results Among 131 492 patients with IBD with a medium follow-up of 9.6 years, we identified 369 cases of NHL and 44 cases of HL. The SIR of NHL was 1.3 (95% CI 1.1 to 1.5) in ulcerative colitis and 1.4 (95% CI 1.2 to 1.7) in Crohn’s disease. We found no compelling heterogeneity in analyses stratified by patient characteristics. We found a similar pattern and magnitude of excess risks for HL. At 10 years, cumulative incidence was 0.26% (95% CI 0.23% to 0.30%) and 0.06% (95% CI 0.04% to 0.08%) for NHL and HL, respectively. Higher excess risks were found among patients with NHL with concomitant primary sclerosing cholangitis (SIR 3.4; 95% CI 2.1 to 5.2) and in those prescribed thiopurines alone (SIR 2.8; 95% CI 1.4 to 5.7) or with anti-TNF-α agents (SIR 5.7; 95% CI 2.7 to 11.9). Conclusion Patients with IBD have a statistically significant increased risk of malignant lymphomas compared with the general population, but the absolute risk remains low.


  • Open Access

    Risk of hepato‐pancreato‐biliary cancer is increased by primary sclerosing cholangitis in patients with inflammatory bowel disease: A population‐based cohort study

    by Jingru Yu, Erle Refsum, Lise M. Helsingen, Trine Folseraas, Alexander Ploner, Paulina Wieszczy, Ishita Barua, Henriette C. Jodal, Espen Melum, Magnus Løberg, et al.

    Background: There is continued uncertainty regarding the risks of hepato‐pancreato‐biliary cancers in patients with inflammatory bowel disease (IBD) with or without concomitant primary sclerosing cholangitis (PSC).Objective: To give updated estimates on risk of hepato‐pancreato‐biliary cancers in patients with IBD, including pancreatic cancer, hepatocellular carcinoma, gall bladder cancer, and intra – and extrahepatic cholangiocarcinoma.Methods: In a population‐based cohort study, we included all patients diagnosed with IBD in Norway and Sweden from 1987 to 2016. The cohort comprised of 141,960 patients, identified through hospital databases and the National Patient Register. Participants were followed through linkage to national cancer, cause of death, and population registries. We calculated absolute risk and standardized incidence ratios (SIRs) of hepato‐pancreato‐biliary cancers by PSC and other clinical characteristics.Results: Of the 141,960 IBD patients, 3.2% were diagnosed with PSC. During a median follow‐up of 10.0 years, we identified 443 biliary tract cancers (SIR 5.2, 95% confidence interval [CI] 4.8–5.7), 161 hepatocellular carcinomas (SIR 2.4, 95% CI 2.0–2.7) and 282 pancreatic cancers (SIR 1.3, 95% CI 1.2–1.5). The relative risks were considerably higher in PSC‐IBD patients, with SIR of 140 (95% CI 123–159) for biliary tract, 38.6 (95% CI 29.2–50.0) for hepatocellular, and 9.0 (95% CI 6.3–12.6) for pancreatic cancer. The SIRs were still slightly increased in non‐PSC‐IBD patients, compared to the general population. For biliary tract cancer, the cumulative probability at 25 years was 15.6% in PSC‐IBD patients, and 0.4% in non‐PSC‐IBD patients.Conclusions: The dramatically increased risks of hepato‐pancreato‐biliary cancers in PSC‐IBD patients support periodic surveillance for these malignancies. While much lower, the excess relative risks in non‐PSC‐IBD patients were not trivial compared to non‐IBD related risk factors.


  • Open Access

    Long‐term colorectal cancer incidence and mortality after adenoma removal in women and men

    by Henriette C. Jodal, Dagmar Klotz, Magnhild Herfindal, Ishita Barua, Petter Tag, Lise M. Helsingen, Erle Refsum, Øyvind Holme, Hans‐Olov Adami, Michael Bretthauer, et al.

    Summary: Background: Women and men with colorectal adenomas are at increased risk of colorectal cancer and colonoscopic surveillance is recommended. However, the long‐term cancer risk remains unknown.Aims: To investigate colorectal cancer incidence and mortality after adenoma removal in women and menMethods: We identified all individuals who had adenomas removed in Norway from 1993 to 2007, with follow‐up through 2018. We calculated standardized incidence ratios (SIR) and incidence‐based mortality ratios (SMR) with 95% confidence intervals (CI) for colorectal cancer in women and men using the female and male population for comparison. We defined high‐risk adenomas as ≥2 adenomas, villous component, or high‐grade dysplasia.Results: The cohort comprised 40 293 individuals. During median follow‐up of 13.0 years, 1079 women (5.5%) and 866 men (4.2%) developed colorectal cancer; 328 women (1.7%) and 275 men (1.3%) died of colorectal cancer. Colorectal cancer incidence was more increased in women (SIR 1.64, 95% CI 1.54‐1.74) than in men (SIR 1.12, 95% CI 1.05‐1.19). Colorectal cancer mortality was increased in women (SMR 1.13, 95% CI 1.02‐1.26) and reduced in men (SMR 0.79, 95% CI 0.71‐0.89). Women with high‐risk adenomas had an increased risk of colorectal cancer death (SMR 1.37, 95% CI 1.19‐1.57); women with low‐risk adenomas (SMR 0.90, 95% CI 0.76‐1.07) and men with high‐risk adenomas had a similar risk (SMR 0.89, 95% CI 0.76‐1.04), while men with low‐risk adenomas had reduced risk (SMR 0.70, 95% CI 0.59‐0.84).Conclusions: After adenoma removal, women had an increased risk of colorectal cancer death, while men had reduced risk, compared to the general female and male populations. Sex‐specific surveillance recommendations after adenoma removal should be considered.


  • Open Access

    Mortality in Norway and Sweden before and after the Covid-19 outbreak: a cohort study

    by Frederik E Juul, Henriette C Jodal, Ishita Barua, Erle Refsum, Ørjan Olsvik, Lise M Helsingen, Magnus Løberg, Michael Bretthauer, Mette Kalager, Louise Emilsson

    Objectives: Norway and Sweden are similar countries regarding ethnicity, socioeconomics and health care. To combat Covid-19, Norway implemented extensive measures such as school closures and lock-downs, while Sweden has been criticised for relaxed measures against Covid-19. We compared the effect of the different national strategies on all-cause and Covid-19 associated mortality. Design: Retrospective cohort. Setting: The countries Norway and Sweden. Participants: All inhabitants. Main outcome measures: We calculated weekly mortality rates (MR) with 95% confidence intervals (CI) per 100,000 individuals as well as mortality rate ratios (MRR) comparing the epidemic year (29 th July, 2019 to 26 th July, 2020) to the four preceding years (July 2015 to July 2019). We also compared Covid-19 associated deaths and mortality rates for the weeks of the epidemic in Norway and Sweden (16 th March to 26 th July, 2020). Results: In Norway, mortality rates were stable during the first three 12-month periods of 2015/16; 2016/17 and 2017/18 (MR 14.8 to 15.1 per 100,000), and slightly lower in the two most recent periods including during epidemic period (2018/19 and 2019/20; 14.5 per 100,000). In Sweden, all-cause mortality was stable during the first three 12-month periods of 2015/16; 2016/17 and 2017/18 (MR 17.2 to 17.5 per 100,000), but lower in the year 2018/19 immediately preceding the epidemic (16.2 per 100,000). Covid-19 associated mortality rates were 0.2 per 100,000 (95%CI 0.1 to 0.4) in Norway and 2.9 (95%CI 1.9 to 3.9) in Sweden. The increase in mortality was confined to individuals in 70 years or older. Conclusions: All-cause mortality remained unaltered in Norway. In Sweden, the observed increase in all-cause mortality during Covid-19 was partly due to a lower than expected mortality preceding the epidemic and the observed excess mortality, was followed by a lower than expected mortality after the first Covid-19 wave. This may suggest mortality displacement. Strengths and limitations of this study: Compares two similar contries in all aspects but the handling of the Covid-19 epidemic Evaluates the mortality for several years before and during the epidemic Provides a possible explanation of the observed mortality changes Discusses the socioeconomic effects of the different strategies in the two countries Does not evaluate cause-specific mortality


  • Open Access

    Trust, threats, and consequences of the COVID-19 pandemic in Norway and Sweden: A comparative survey

    by Lise M. Helsingen, Erle Refsum, Dagryn Kyte Gjostein, Magnus Loberg, Michael Bretthauer, Mette Kalager, Louise Emilsson

    Objectives: Norway and Sweden, two neighboring countries with similar populations, health care systems and socioeconomics, have reacted differently to the COVID-19 pandemic. Norway closed all kindergartens, schools and universities, and banned sports and cultural activities, while Sweden kept most institutions and trainings facilities open. We aimed to compare peoples' attitudes towards authorities and control measures, and effects on life in Norway and Sweden. Design: Anonymous web-based surveys for individuals age 15 or older distributed through Facebook using the snowball method. Setting: Norway and Sweden, mid-March to mid-April, 2020. Participants: Altogether, 3,508 individuals participated in the survey; 3000 in Norway and 508 in Sweden. 79% of the participants were women, 60% of the Norwegians and 47% of the Swedes were between 30-49 years, and around 45% of the participants in both countries had more than 4 years of higher education. Outcome measures: Perceived threat of the pandemic, views on infection control measures, and impact on daily life. We performed descriptive analyses of the responses and compared the two countries. Results: People had high trust in the health services in both countries, but differed in the degree of trust in their government (17% had high trust in Norway and 37% in Sweden). More Norwegians than Swedes agreed that school closure was a good measure (66% Norway and 18% in Sweden), and that countries with open schools were irresponsible (65% in Norway and 23% in Sweden). About the same amount responded that COVID-19 was a large to very large threat to the population (53% in Norway and 58% in Sweden), whereas more Norwegians than Swedes responded that the threat from repercussions of the mitigation measures were large or very large (71% in Norway and 56% in Sweden). Compliance with infection preventive measures was high and similar in the two countries (more than 98%). In Norway, 69% lived a more sedentary life during the pandemic versus 50% in Sweden; and Norwegians reported they ate more than Swedes (44% in Norway and 33% in Sweden). Conclusion: Sweden, with less restrictive measures against the COVID-19 pandemic, had a higher level of trust in the authorities, while Norwegians reported a more negative lifestyle during the pandemic. The level of trust in the health care system and self-reported compliance with preventive measures was high in both countries.


  • Open Access

    Personvern – en hinderløype

    by Erle Refsum, Lise M. Helsingen, Henriette C. Jodal, Magnus Løberg, Njål Høstmælingen, Mette Kalager

    15.02.2019: Debatt - Vi brukte fire år på å forhandle med personvernombud på norske sykehus før forskningsprosjektet kunne komme i gang.